Bacteriophage therapy as an innovative strategy for the treatment of Periprosthetic Joint Infection: a systematic review
International Orthopaedics · 2024
DOI: 10.1007/s00264-024-06295-1 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Orthopaedics, 2024. Verfasst von Shengdong Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery and Sport Medicine, FIFA Medical Center of Excellence, Croix-Rousse Hospital, Lyon University Hospital, Lyon, France. Hauptthemen laut MEDLINE: Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee, Phage Therapy, Prosthesis-Related Infections. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hospices Civils de Lyon.
Abstract (Originalsprache)
Background
Periprosthetic Joint Infection (PJI) following hip and knee arthroplasty is a catastrophic complication in orthopaedic surgery. It has long been a key focus for orthopaedic surgeons in terms of prevention and management. With the increasing incidence of antibiotic resistance in recent years, finding more targeted treatment methods has become an increasingly urgent issue. Bacteriophage Therapy (BT) has emerged as a promising adjunctive treatment for bone and joint infections in recent years. It not only effectively kills bacteria but also demonstrates significant anti-biofilm activity, garnering substantial clinical interest due to its demonstrated efficacy and relatively low incidence of adverse effects.
Purpose
This review aims to systematically evaluate the efficacy and safety of bacteriophage therapy in treating PJI following hip and knee arthroplasty, providing additional reference for its future clinical application.
Methods
Following predefined inclusion and exclusion criteria, our team conducted a systematic literature search across seven databases (PubMed, Embase, Web of Science, Cochrane Library, ClinicalTrials.gov, CNKI, and WanFang Database). The search was conducted up to May 2024 and included multiple clinical studies on the use of bacteriophage therapy for treating PJI after hip and knee arthroplasty to assess its efficacy and safety.
Results
This systematic review included 16 clinical studies after screening, consisting of 15 case reports and one prospective controlled clinical trial, involving a total of 42 patients with PJI treated with bacteriophage therapy. The average patient age was 62.86 years, and 43 joints were treated, with patients undergoing an average of 5.25 surgeries. The most common pathogen in these infections was Staphylococcus aureus , accounting for 18 cases. 33 patients received cocktail therapy, while nine were treated with a single bacteriophage preparation. Additionally, all patients underwent suppressive antibiotic therapy (SAT) postoperatively. All patients were followed up for an average of 13.55 months. There were two cases of recurrence, one of which resulted in amputation one year postoperatively. The remaining patients showed good recovery outcomes. Overall, the results from the included studies indicate that bacteriophage therapy effectively eradicates infectious strains in various cases of PJI, with minimal side effects, demonstrating promising clinical efficacy.
Conclusion
In the treatment of PJI following hip and knee arthroplasty, bacteriophages, whether used alone or in combination as cocktail therapy, have shown therapeutic potential. However, thorough preoperative evaluation is essential, and appropriate bacteriophage types and treatment regimens must be selected based on bacteriological evidence. Future large-scale, randomized controlled, and prospective trials are necessary to validate the efficacy and safety of this therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopedic Surgery and Sport Medicine, FIFA Medical Center of Excellence, Croix-Rousse Hospital, Lyon University Hospital, Lyon, France.
- IFSTTAR, LBMC UMR_T9406, University Claude Bernard Lyon 1, University of Lyon, Lyon, France.
- Orthopedics and Traumatology, Vita-Salute San Raffaele University, Milan, Italy.
- Department of Orthopedic Surgery and Traumatology, Faculty of Medicine, Minia University, Minia, Egypt.
- Centre interrégional de Référence pour la prise en charge des Infections Ostéo-Articulaires complexes (CRIOAc Lyon), Hospices Civils de Lyon, Lyon, France.
- Service de Maladies Infectieuses et Tropicales, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.
Förderung
- Hospices Civils de Lyon
Zitieren
APA
Yang, S., Mukh, A. A., Abdelatif, E., Schmidt, A., Batailler, C., Ferry, T., & Lustig, S. (2024). Bacteriophage therapy as an innovative strategy for the treatment of Periprosthetic Joint Infection: a systematic review. International Orthopaedics. https://doi.org/10.1007/s00264-024-06295-1
Vancouver
Yang S, Mukh AA, Abdelatif E, Schmidt A, Batailler C, Ferry T, et al. Bacteriophage therapy as an innovative strategy for the treatment of Periprosthetic Joint Infection: a systematic review. International Orthopaedics. 2024. doi:10.1007/s00264-024-06295-1
BibTeX
@article{Yang2024,
author = {Yang, Shengdong and Mukh, Assala Abu and Abdelatif, Elsayed and Schmidt, Axel and Batailler, Cécile and Ferry, Tristan and Lustig, Sébastien},
title = {Bacteriophage therapy as an innovative strategy for the treatment of Periprosthetic Joint Infection: a systematic review},
journal = {International Orthopaedics},
year = {2024},
doi = {10.1007/s00264-024-06295-1}
}
EUVIMED